Johnson & Johnson has temporarily stopped COVID-19 vaccine trials after a participant fell ill, according to yahoo!news. The participant’s illness is being reviewed by the company’s safety and clinical physicians.
- Pauses are normal for major trials, and the current one is different from the “regulatory hold” required by authorities.
- It is normal for some participants in studies to get placebos, and unclear whether the person with illness received a placebo or treatment.
- J&J had kicked off the final 60,000-personal trials last months, and the results are expected by the end of the year or early 2021
J&J stock is declining on vaccine trial pause. JNJ: NYSE is down on premarket 1.87%
XTB
